GET A QUOTE

Toll-Like Receptor 9 (TLR9): A Key Player in Innate Immunity

Structure and Localization

TLR9 is a pattern recognition receptor primarily located in the endosomes of immune cells, particularly plasmacytoid dendritic cells and B cells. The receptor consists of leucine-rich repeat motifs in its ectodomain, a transmembrane domain, and a cytoplasmic Toll/IL-1 receptor (TIR) domain.

The receptor’s structure includes approximately 25-29 leucine-rich repeats (LRRs) that form a horseshoe-shaped solenoid, which is essential for ligand recognition. The proteolytic processing of TLR9 in endosomes, mediated by cathepsins and other proteases, generates a functionally mature form of the receptor. This processing event occurs between LRR14 and LRR15, creating an N-terminal fragment of approximately 65 kDa and a C-terminal fragment of about 95 kDa.

The endosomal localization of TLR9 is maintained through various trafficking mechanisms. The transmembrane protein UNC93B1 plays a crucial role in trafficking TLR9 from the endoplasmic reticulum to endolysosomes. Additionally, the chaperone protein gp96 and other factors such as AP-3 and PRAT4A are involved in proper TLR9 trafficking and localization.

Recognition and Ligand Specificity

TLR9 specifically recognizes unmethylated CpG motifs, which are abundant in bacterial and viral DNA but rare in vertebrate genomes. This receptor can detect synthetic oligonucleotides containing CpG motifs (CpG ODNs) as well as natural pathogen-derived DNA.

Different classes of CpG ODNs (A, B, and C) have been identified, each with distinct structural characteristics and immunostimulatory properties. Class A CpG ODNs primarily induce type I interferon production in plasmacytoid dendritic cells, while Class B CpG ODNs strongly activate B cells. Class C CpG ODNs combine properties of both A and B classes.

The specificity of TLR9 for unmethylated CpG motifs is enhanced by the preferential recognition of specific flanking sequences. The optimal human TLR9-stimulating sequence is typically GTCGTT, while mouse TLR9 preferentially recognizes GACGTT motifs.

Signalling Pathway and Immune Response

When a molecule binds to TLR 9 the adaptor protein My86 is called upon to start a chain of signals that eventually leads to the activation of transcription factors, like NF Kappa B and IRF7. This action results in the creation of substances such as type one interferons TNF-alpha and IL-12. The chain of signals also sparks the growth of B cells antibody production and the development of cells showing how TLR9 plays a role, in linking innate and adaptive immunity

The signalling cascade includes molecules and regulatory steps, in the process. As MyD88 is recruited it leads to the formation of a complex known as the “myddosome,” which consists of IRAK1, IRK4, and TRAF6. This complex then triggers TAKI activation, resulting in the activation of both the NF-kB and MAPK pathways. In cells the TLR9 signal pathway also activates IRF7 through IRAKI and IKK-alpha resulting, in a strong production of type I interferons.

The cellular responses to TLR9 activation are cell-type specific. In B cells, TLR9 signalling promotes proliferation, immunoglobulin class switching, and plasma cell differentiation. In plasmacytoid dendritic cells, it induces massive type I interferon production and maturation. These responses are carefully regulated by various mechanisms, including negative regulators such as SOCS proteins and A20, to prevent excessive inflammation.

Therapeutic Applications and Clinical Relevance

TLR9 have become a focus, in the treatment of illnesses with CpG ODNs being explored as enhancers for immune responses against infections and cancers when used as vaccine boosters. Adversely TLR9 inhibitors display potential in managing disorders linked to immune responses that worsen health conditions. New studies have highlighted its involvement in issues making them appealing targets, for therapies aimed at modulating the immune system.

In the field of cancer immunotherapy testing is currently underway for TLR9 agonists both, as treatments and in conjunction with existing therapies with findings emerging from clinical trials across different types of cancer such as melanoma lymphoma and non-small cell lung cancer These activators function by stimulating immune responses, against tumors and improving the efficacy of traditional cancer therapies

In the realm of vaccine creation CpG ODNs have shown promise as enhancers. They have been effectively utilized in vaccines, against hepatitis B virus. Are under scrutiny for their use in vaccines for infections like influenza and COVID 19. The capacity of TLR9 stimulants to boost both antibodies based, and cell mediated immune reactions renders them especially beneficial, for vaccine formulation.

Autoimmune disorders, like systemic lupus erythematosus (SLE) may benefit from the inhibition of TLR toll like receptor signalling for therapeutic purposes Drugs that block TLR inhibit or antagonize its activity are under development to help decrease inflammation in such situations However it’s important to note that the function of TLR, in autoimmunity is multifaceted as it may exhibit both harmful effects depending on the circumstances.

Suitable ELISA Kits

Online Enquiry Form

"*" indicates required fields

Please check mark information required:

TESTIMONIALS arrow icon

Your secretory IgA ELISA gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA assay performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA assay's from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford